192 related articles for article (PubMed ID: 21712498)
21. Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers.
Pham PA; la Porte CJ; Lee LS; van Heeswijk R; Sabo JP; Elgadi MM; Piliero PJ; Barditch-Crovo P; Fuchs E; Flexner C; Cameron DW
Antimicrob Agents Chemother; 2009 Oct; 53(10):4385-92. PubMed ID: 19667285
[TBL] [Abstract][Full Text] [Related]
22. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers.
Martin PD; Warwick MJ; Dane AL; Hill SJ; Giles PB; Phillips PJ; Lenz E
Clin Ther; 2003 Nov; 25(11):2822-35. PubMed ID: 14693307
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of rosuvastatin/olmesartan fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects.
Son H; Roh H; Lee D; Chang H; Kim J; Yun C; Park K
Clin Ther; 2013 Jul; 35(7):915-22. PubMed ID: 23810276
[TBL] [Abstract][Full Text] [Related]
24. Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
Mazza F; Stefanutti C; Di Giacomo S; Vivenzio A; Fraone N; Mazzarella B; Bucci A
Am J Cardiovasc Drugs; 2008; 8(4):265-70. PubMed ID: 18690760
[TBL] [Abstract][Full Text] [Related]
25. Darunavir/ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers.
Sekar VJ; Spinosa-Guzman S; De Paepe E; De Pauw M; Vangeneugden T; Lefebvre E; Hoetelmans RM
J Clin Pharmacol; 2008 Jan; 48(1):60-5. PubMed ID: 18094220
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic and pharmacodynamic profile of rosuvastatin in patients with end-stage renal disease on chronic haemodialysis.
Birmingham BK; Swan SK; Puchalski T; Mitchell P; Azumaya C; Zalikowski J; Wang Y
Clin Drug Investig; 2013 Apr; 33(4):233-41. PubMed ID: 23494963
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment.
Simonson SG; Martin PD; Mitchell P; Schneck DW; Lasseter KC; Warwick MJ
Eur J Clin Pharmacol; 2003 Feb; 58(10):669-75. PubMed ID: 12610743
[TBL] [Abstract][Full Text] [Related]
28. Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir.
Malvestutto CD; Ma Q; Morse GD; Underberg JA; Aberg JA
J Acquir Immune Defic Syndr; 2014 Dec; 67(4):390-6. PubMed ID: 25202920
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design.
Polli JW; Hussey E; Bush M; Generaux G; Smith G; Collins D; McMullen S; Turner N; Nunez DJ
Xenobiotica; 2013 Jun; 43(6):498-508. PubMed ID: 23256625
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of darunavir (TMC114) and atazanavir during coadministration in HIV-negative, healthy volunteers.
Sekar VJ; Lefebvre E; De Marez T; Spinosa-Guzman S; De Pauw M; De Paepe E; Vangeneugden T; Hoetelmans RM
Drugs R D; 2007; 8(4):241-8. PubMed ID: 17596110
[TBL] [Abstract][Full Text] [Related]
31. Rosuvastatin: a review of its use in the management of dyslipidemia.
Scott LJ; Curran MP; Figgitt DP
Am J Cardiovasc Drugs; 2004; 4(2):117-38. PubMed ID: 15049723
[TBL] [Abstract][Full Text] [Related]
32. Single-dose, 2-way crossover, bioequivalence study of two rosuvastatin formulations in normal healthy subjects under fasting conditions.
Trabelsi F; Bartůnek A; Vlavonou R; Navrátilová L; Dubé C; Tanguay M; Hauser T
Int J Clin Pharmacol Ther; 2012 Oct; 50(10):741-50. PubMed ID: 22762855
[TBL] [Abstract][Full Text] [Related]
33. Potential association between rosuvastatin use and high atazanavir trough concentrations in ritonavir-treated HIV-infected patients.
Gervasoni C; Riva A; Rizzardini G; Clementi E; Galli M; Cattaneo D
Antivir Ther; 2015; 20(4):449-51. PubMed ID: 25279606
[TBL] [Abstract][Full Text] [Related]
34. Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin.
Aquilante CL; Kiser JJ; Anderson PL; Christians U; Kosmiski LA; Daily EB; Hoffman KL; Hopley CW; Predhomme JA; Schniedewind B; Sidhom MS
J Clin Pharmacol; 2012 Nov; 52(11):1725-38. PubMed ID: 22174437
[TBL] [Abstract][Full Text] [Related]
35. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin.
White CM
J Clin Pharmacol; 2002 Sep; 42(9):963-70. PubMed ID: 12211221
[TBL] [Abstract][Full Text] [Related]
36. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
Arvieux C; Tribut O
Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
[TBL] [Abstract][Full Text] [Related]
37. An evaluation of rosuvastatin: pharmacokinetics, clinical efficacy and tolerability.
Crouse JR
Expert Opin Drug Metab Toxicol; 2008 Mar; 4(3):287-304. PubMed ID: 18363544
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers.
Sekar V; Lavreys L; Van de Casteele T; Berckmans C; Spinosa-Guzman S; Vangeneugden T; De Pauw M; Hoetelmans R
Antimicrob Agents Chemother; 2010 Oct; 54(10):4440-5. PubMed ID: 20660678
[TBL] [Abstract][Full Text] [Related]
39. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
40. ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans.
Zhu T; Awni WM; Hosmane B; Kelly MT; Sleep DJ; Stolzenbach JC; Wan K; Chira TO; Pradhan RS
J Clin Pharmacol; 2009 Jan; 49(1):63-71. PubMed ID: 18952910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
